Manfidokimab vs QL2108

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline

Manfidokimab

Developed by Akeso

Phase 3 in Atopic Dermatitismonoclonal antibody
Partial signal

NCT06383468 · Phase 3 · status unknown

This Phase 3 trial randomly assigned adults with moderate-to-severe atopic dermatitis to manfidokimab (AK120) or placebo, both delivered by subcutaneous injection, under quadruple-blind conditions, with the proportion of patients achieving EASI-75 (75% improvement in eczema severity) at week 16 as the primary endpoint. No results have been posted, so this remains a well-designed, adequately sized, blinded, placebo-controlled trial whose findings are not yet known.

Next expected readout: July 2027 · NCT06767540 (registry estimate)

No aligned efficacy figure on record for this race.

QL2108

Developed by Qilu Pharmaceutical

Phase 3 in Atopic Dermatitismonoclonal antibody (biosimilar)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT06884891 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointManfidokimabQL2108
EASI-75—Trial running · NCT06767540—Trial running · NCT06884891
IGA 0/1 with 2-point improvement—Trial running · NCT06767540—Trial running · NCT06884891
EASI-90—Trial running · NCT06767540—Trial running · NCT06884891
EASI, % change—Trial running · NCT06767540—Trial running · NCT06884891

EASI-75

Manfidokimab
—Trial running · NCT06767540
QL2108
—Trial running · NCT06884891

IGA 0/1 with 2-point improvement

Manfidokimab
—Trial running · NCT06767540
QL2108
—Trial running · NCT06884891

EASI-90

Manfidokimab
—Trial running · NCT06767540
QL2108
—Trial running · NCT06884891

EASI, % change

Manfidokimab
—Trial running · NCT06767540
QL2108
—Trial running · NCT06884891
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Manfidokimab: no structured comparison results are available for Atopic Dermatitis.

QL2108: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Manfidokimab's landscape · QL2108's landscape